Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 11Breast Neoplasms 8Prostatic Neoplasms 7Colorectal Neoplasms 7Carcinoma, Non-Small-Cell Lung 6Neoplasms 5Melanoma 5COVID-19 4Multiple Myeloma 3Lung Neoplasms 3Gastrointestinal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Unspecified Adult Solid Tumor, Protocol Specific 2Solid Tumor 2Recurrence 2Rectal Neoplasms 2Ovarian Neoplasms 2Neoplasms, Plasma Cell 2Neoplasm Metastasis 2Leukemia 2Glioblastoma 2Cholangiocarcinoma 2Adenocarcinoma of Lung 2Adenocarcinoma 2Urologic Diseases 1Untreated Resectable Pancreatic Adenocarcinoma 1Small Cell Lung Carcinoma 1Sarcoma, Clear Cell 1Sarcoma 1

Interventions

Taxes 1Hydroxychloroquine 1Gemcitabine 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Untreated Resectable Pancreatic Adenocarcinoma × Hydroxychloroquine × Clear all
NCT04669197 2025-08-15

Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydrochloroquine as Treatment in Untreated Pancreas Cancer

HonorHealth Research Institute

Phase 2 Active not recruiting
19 enrolled
Gastrointestinal

Untreated Resectable Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡